HBV cccDNA转录代谢调控机制及沉默清除策略

宰文静; 陈捷亮; 袁正宏

doi:10.3969/j.issn.1001-5256.2020.05.006

HBV cccDNA转录代谢调控机制及沉默清除策略

DOI: 10.3969/j.issn.1001-5256.2020.05.006

复旦大学上海医学院基础医学院，病原生物学系医学分子病毒学教育部/卫健委重点实验室

基金项目:

国家自然科学基金项目（81974304,91842309）；

详细信息

中图分类号: R512.62
计量
- 文章访问数: 1313
- HTML全文浏览量: 61
- PDF下载量: 341
- 被引次数: 0
出版历程
- 出版日期: 2020-05-20

Regulatory mechanisms of the transcription and metabolism of hepatitis B virus covalently closed circular DNA and strategies for silencing and elimination

MOE & NHC Key Laboratory of Medical Molecular Virology, Department of Medical Microbiology and Parasitology, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai 200032, China

Research funding:

摘要

摘要:
已知HBV cccDNA在感染肝细胞的细胞核内以微染色体的形式持续稳定存在,难以被靶向调控和清除。围绕HBV cccDNA持续沉默或降解清除机制及策略的研究是当前慢性乙型肝炎"功能性治愈"目标下的重点。介绍了目前对cccDNA基本生物学特性、转录和代谢调控机制及相关宿主因子的认知,重点分析了cccDNA沉默清除的可能途径和靶向调控策略。
- 乙型肝炎病毒 /
- DNA,环状 /
- 代谢 /
- 转录调控 /
- 抗病毒策略
Abstract:
It is known that hepatitis B virus(HBV) covalently closed circular DNA(cccDNA) persists in the nucleus of infected hepatocytes in the form of minichromosome and is difficult to target and eliminate. Studies on the mechanisms and strategies for persistent silencing or elimination of HBV cccDNA are the focus achieving for “functional cure” of chronic hepatitis B. This article introduces the current knowledge on the basic biological features of cccDNA, regulatory mechanisms of transcription and metabolism, and related host factors, with a focus on the potential pathways and strategies for cccDNA silencing or elimination.
- hepatitis B virus /
- DNA,circular /
- metabolism /
- transcription regulation /
- antiviral strategies

HTML全文

参考文献(50)

[1] LIN CL, YANG HC, KAO JH. Hepatitis B virus:New therapeutic perspectives[J]. Liver Int, 2016, 36(Suppl 1):85-92.

[2] KÖNIGER C, WINGERT I, MARSMANN M, et al. Involvement of the host DNA-repair enzyme TDP2 in formation of the covalently closed circular DNA persistence reservoir of hepatitis B viruses[J]. Proc Natl Acad Sci U S A, 2014, 111(40):e4244-e4253.

[3] KITAMURA K, QUE L, SHIMADU M, et al. Flap endonuclease1 is involved in cccDNA formation in the hepatitis B virus[J].PLoS Pathog, 2018, 14(6):e1007124.

[4] WEI L, PLOSS A. Core components of DNA lagging strand synthesis machinery are essential for hepatitis B virus cccDNA formation[J]. Nat Microbiol, 2020.[Online ahead of print]

[5] LARAS A, KOSKINAS J, DIMOU E, et al. Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients[J]. Hepatology,2006, 44(3):694-702.

[6] LENTZ TB, LOEB DD. Roles of the envelope proteins in the amplification of covalently closed circular DNA and completion of synthesis of the plus-strand DNA in hepatitis B virus[J]. J Virol, 2011, 85(22):11916-11927.

[7] WERLE-LAPOSTOLLE B, BOWDEN S, LOCARNINI S, et al.Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy[J].Gastroenterology, 2004, 126(7):1750-1758.

[8] LAI CL, WONG D, IP P, et al. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B[J]. J Hepatol, 2017, 66(2):275-281.

[9] TSIANG M, GIBBS CS. Analysis of hepatitis B virus dynamics and its impact on antiviral development[J]. Methods Mol Med, 2004, 96:361-377.

[10] ADDISON WR, WALTERS KA, WONG WW, et al. Half-life of the duck hepatitis B virus covalently closed circular DNA pool in vivo following inhibition of viral replication[J]. J Virol, 2002,76(12):6356-6363.

[11] HUANG Q, ZHOU B, CAI D, et al. Rapid turnover of HBV cccDNA indicated by monitoring emergence and reversion of signature-mutation in treated chronic hepatitis B patients[J].Hepatology, 2020.[Online ahead of print]

[12] BOCK CT, SCHWINN S, LOCARNINI S, et al. Structural organization of the hepatitis B virus minichromosome[J]. J Mol Biol, 2001, 307(1):183-196.

[13] KNIPE DM, CLIFFE A. Chromatin control of herpes simplex virus lytic and latent infection[J]. Nat Rev Microbiol, 2008, 6(3):211-221.

[14] MOREAU P, COURNAC A, PALUMBO GA, et al. Tridimensional infiltration of DNA viruses into the host genome shows preferential contact with active chromatin[J]. Nat Commun,2018, 9(1):4268.

[15] ZHANG Y, MAO R, YAN R, et al. Transcription of hepatitis B virus covalently closed circular DNA is regulated by CpG methylation during chronic infection[J]. PLoS One, 2014, 9(10):e110442.

[16] RAMIÈRE C, SCHOLTÈS C, DIAZ O, et al. Transactivation of the hepatitis B virus core promoter by the nuclear receptor FXRalpha[J]. J Virol, 2008, 82(21):10832-10840.

[17] KIM BK, LIM SO, PARK YG. Requirement of the cyclic adenosine monophosphate response element-binding protein for hepatitis B virus replication[J]. Hepatology, 2008, 48(2):361-373.

[18] RALL LB, STANDRING DN, LAUB O, et al. Transcription of hepatitis B virus by RNA polymerase II[J]. Mol Cell Biol,1983, 3(10):1766-1773.

[19] TROPBERGER P, MERCIER A, ROBINSON M, et al. Mapping of histone modifications in episomal HBV cccDNA uncovers an unusual chromatin organization amenable to epigenetic manipulation[J]. Proc Natl Acad Sci U S A, 2015, 112(42):e5715-e5724.

[20] FLECKEN T, MEIER MA, SKEWES-COX P, et al. Mapping the heterogeneity of histone modifications on hepatitis B virus DNA using liver needle biopsies obtained from chronically infected patients[J]. J Virol, 2019, 93(9):e02036-e02018.

[21] ZHANG W, CHEN J, WU M, et al. PRMT5 restricts hepatitis B virus replication through epigenetic repression of covalently closed circular DNA transcription and interference with pregenomic RNA encapsidation[J]. Hepatology, 2017, 66(2):398-415.

[22] REN JH, HU JL, CHENG ST, et al. SIRT3 restricts hepatitis B virus transcription and replication through epigenetic regulation of covalently closed circular DNA involving suppressor of variegation 3-9 homolog 1 and SET domain containing 1A histone methyltransferases[J]. Hepatology, 2018, 68(4):1260-1276.

[23] DUGGAL NK, EMERMAN M. Evolutionary conflicts between viruses and restriction factors shape immunity[J]. Nat Rev Immunol, 2012, 12(10):687-695.

[24] WANG YX, NIKLASCH M, LIU T, et al. Interferon-inducible MX2 is a host restriction factor of hepatitis B virus replication[J]. J Hepatol, 2020, 72(5):865-876.

[25] CHEN EQ, DAI J, BAI L, et al. The efficacy of zinc finger antiviral protein against hepatitis B virus transcription and replication in tansgenic mouse model[J]. Virol J, 2015, 12:25.

[26] BELLONI L, ALLWEISS L, GUERRIERI F, et al. IFN-αinhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome[J]. J Clin Invest, 2012, 122(2):529-537.

[27] LIU F, CAMPAGNA M, QI Y, et al. Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes[J]. PLoS Pathog,2013, 9(9):e1003613.

[28] PALUMBO GA, SCISCIANI C, PEDICONI N, et al. Correction:IL6 inhibits HBV transcription by targeting the epigenetic control of the Nuclear cccDNA minichromosome[J]. PLoS One, 2015, 10(12):e0145555.

[29] REHERMANN B, FERRARI C, PASQUINELLI C, et al. The hepatitis B virus persists for decades after patients’ recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response[J]. Nat Med, 1996, 2(10):1104-1108.

[30] COUGOT D, WU Y, CAIRO S, et al. The hepatitis B virus X protein functionally interacts with CREB-binding protein/p300in the regulation of CREB-mediated transcription[J]. J Biol Chem, 2007, 282(7):4277-4287.

[31] BELLONI L, POLLICINO T, de NICOLA F, et al. Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function[J]. Proc Natl Acad Sci U S A,2009, 106(47):19975-19979.

[32] MURPHY CM, XU Y, LI F, et al. Hepatitis B virus X protein promotes degradation of SMC5/6 to enhance HBV replication[J]. Cell Rep, 2016, 16(11):2846-2854.

[33] BAUMERT TF, RÖSLER C, MALIM MH, et al. Hepatitis B virus DNA is subject to extensive editing by the human deaminase APOBEC3C[J]. Hepatology, 2007, 46(3):682-689.

[34] STRAY SJ, BOURNE CR, PUNNA S, et al. A heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly[J]. Proc Natl Acad Sci U S A, 2005, 102(23):8138-8143.

[35] GUIDOTTI LG, ISHIKAWA T, HOBBS MV, et al. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes[J]. Immunity, 1996, 4(1):25-36.

[36] GUIDOTTI LG, ROCHFORD R, CHUNG J, et al. Viral clearance without destruction of infected cells during acute HBV infection[J]. Science, 1999, 284(5415):825-829.

[37] XIA Y, STADLER D, LUCIFORA J, et al. Interferon-γand tumor necrosis factor-αproduced by T cells reduce the HBV persistence form, cccDNA, without cytolysis[J]. Gastroenterology, 2016, 150(1):194-205.

[38] GUIDOTTI LG, BORROW P, HOBBS MV, et al. Viral cross talk:Intracellular inactivation of the hepatitis B virus during an unrelated viral infection of the liver[J]. Proc Natl Acad Sci U S A, 1996, 93(10):4589-4594.

[39] LUCIFORA J, XIA Y, REISINGER F, et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA[J]. Science, 2014, 343(6176):1221-1228.

[40] THIMME R, WIELAND S, STEIGER C, et al. CD8(+)T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection[J]. J Virol, 2003, 77(1):68-76.

[41] ZHANG Z, ZHANG JY, WHERRY EJ, et al. Dynamic programmed death 1 expression by virus-specific CD8 T cells correlates with the outcome of acute hepatitis B[J]. Gastroenterology, 2008, 134(7):1938-1949, 1949.e1-3.

[42] MENG Z, CHEN Y, LU M. Advances in targeting the innate and adaptive immune systems to cure chronic hepatitis B virus infection[J]. Front Immunol, 2019, 10:3127.

[43] LUTGEHETMANN M, VOLZ T, KÖPKE A, et al. In vivo proliferation of hepadnavirus-infected hepatocytes induces loss of covalently closed circular DNA in mice[J]. Hepatology,2010, 52(1):16-24.

[44] AYDIN I, SCHELHAAS M. Viral genome tethering to host cell chromatin:Cause and consequences[J]. Traffic, 2016, 17(4):327-340.

[45] SUMMERS J, JILBERT AR, YANG W, et al. Hepatocyte turnover during resolution of a transient hepadnaviral infection[J].Proc Natl Acad Sci U S A, 2003, 100(20):11652-11659.

[46] GUO JT, ZHOU H, LIU C, et al. Apoptosis and regeneration of hepatocytes during recovery from transient hepadnavirus infections[J]. J Virol, 2000, 74(3):1495-1505.

[47] ALLWEISS L, VOLZ T, GIERSCH K, et al. Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo[J]. Gut,2018, 67(3):542-552.

[48] DONG C, QU L, WANG H, et al. Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication[J]. Antiviral Res, 2015, 118:110-117.

[49] CHEN J, ZHANG W, LIN J, et al. An efficient antiviral strategy for targeting hepatitis B virus genome using transcription activator-like effector nucleases[J]. Mol Ther, 2014, 22(2):303-311.

[50] BLOOM K, MAEPA MB, ELY A, et al. Gene therapy for chronic HBV-can we eliminate cccDNA?[J]. Genes(Basel),2018, 9(4):207.

施引文献

资源附件(0)

访问统计